|Articles|October 19, 2007
A Healthy Outlook for Oncology?
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end? IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.
Advertisement
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end?
IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.
Click
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Direct-to-patient: pharma’s next power move
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
